Patents
2017.09.01
TAHO obtained U.S. patent approval for TAH9922 Atomoxetine oral solution, a child friendly ADHD mediation.
TAHO received patent allowance from the United States Patent and Trademark Office, for the TAH9922 Atomoxetine oral solution, a chiled friendly ADHD medication.
About TAH9922
TAH9922 is an oral liquid for children with ADHD. In order to avoid the difficulty of swallowing oral tablet, the product was developed as a liquid form to enhance children's compliance and improve palatability. According to IMS Data in 2015, the total market size of pediatric ADHD drugs in the United States is approximately NT$31 billion. The revenue generated by the new dosage form of Atomoxetine drug developed by TAHO will vary by the actual licensing or sales condition in the future.
About TAH9922
TAH9922 is an oral liquid for children with ADHD. In order to avoid the difficulty of swallowing oral tablet, the product was developed as a liquid form to enhance children's compliance and improve palatability. According to IMS Data in 2015, the total market size of pediatric ADHD drugs in the United States is approximately NT$31 billion. The revenue generated by the new dosage form of Atomoxetine drug developed by TAHO will vary by the actual licensing or sales condition in the future.